What is Perrigo Company's skin health — net sales?

Perrigo Company (PRGO) reported skin health — net sales of $161.8M in Q2 2026.

What does skin health — net sales mean?

This metric represents the total revenue generated from the sale of products within the company's Skin Health segment, which typically includes dermatological treatments, skincare solutions, and related therapeutic products. It serves as a key indicator of the company's market penetration and consumer demand within the specialized skin health category. Tracking this figure allows investors to assess the growth trajectory and competitive performance of the company's dermatological portfolio relative to broader consumer health trends.

Perrigo Company (PRGO) Skin Health — Net Sales

Screener

Other product segments

Oral Care

$354.4M-5.4%

Upper Respiratory

$178.4M-1.6%

Healthy Lifestyle

$157.8M+2.0%

Pain & Sleep

$124.6M—

Digestive Health

$115.7M-3.4%

Women's Health

$64.8M+3.3%

Similar metrics at other companies

KVUESkin Health and Beauty — Net Sales

$1.11B+5.1%

NATRGeneral health — Net Sales

$48.9M+3.2%

ODCAnimal Health & Nutrition — Net Sales

$6.36M+10.2%

IFFHealth & Biosciences — Net Sales

$595M+10.2%

KVUEEssential Health — Net Sales

$1.25B+2.3%

CLXHealth and Wellness — Net Sales

$860M+16.1%

Other financials

Income statement

See full

Revenue$1.0B-3.2%

Gross profit$313.9M-13.5%

Operating income$23.5M-48.2%

Net income$74.5M+987%

EPS (diluted)$0.53+983%

Balance sheet

See full

Cash & equivalents$399.7M-12.0%

Total debt$3.5B-10.3%

Total equity$2.5B-43.7%

Total assets$7.6B-24.6%

Cash flow

See full

Operating cash flow-$113.6M-76.1%

CapEx$14.3M-25.5%

Free cash flow-$127.4M-41.6%

Valuation

See full

Market cap$1.74B-46.4%

Enterprise value$4.82B-27.7%

P/S0.4×-0.3×

Profitability

See full

Gross margin33.3%-2.5pp

Operating margin-37.7%-44.3pp

Net margin-41.9%-43.9pp

FCF margin4.2%-2.0pp

Returns & leverage

See full

Return on equity-49.6%-51.6pp

Debt / equity1.4×+0.5×

Current ratio2.3×0.0×

Where this comes from

Reported directly by Perrigo Company in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Perrigo Company’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 1:44 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001585364-26-000145

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025	Six Months Ended / June 27, 2026	Six Months Ended / June 28, 2025
Pain & Sleep	124.6	142.8	231.2	272.5
Total Self Care	$576.6	$598.6	$1,119.9	$1,212.8
Specialty Care
Skin Health	$161.8	$170.3	$313.7	$319.9
Women's Health	64.8	62.7	119.9	112.3
Total Specialty Care	$226.6	$233.1	$433.6	$432.2
Infant Formula	$100.9	$82.0	$190.6	$169.8
All Other(1)	$118.6	$142.7	$247.8	$285.4

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Perrigo Company's skin health — net sales?: Perrigo Company (PRGO) reported skin health — net sales of $161.8M in Q2 2026.
What does skin health — net sales mean?: This metric represents the total revenue generated from the sale of products within the company's Skin Health segment, which typically includes dermatological treatments, skincare solutions, and related therapeutic products. It serves as a key indicator of the company's market penetration and consumer demand within the specialized skin health category. Tracking this figure allows investors to assess the growth trajectory and competitive performance of the company's dermatological portfolio relative to broader consumer health trends.